ATTRACT Study | ATTRACT-2 | Researching ASA404 In Cancer Treatment
ATTRACT Clinical Trial Website - ATTRACT Logo
Search This Website:
Novartis Oncology Logo
U.S. Flag - Click If U.S. Resident for U.S. ATTRACT Clinical Trial Website Click here to email this page Click here to print this page
Antivascular Targeted Therapy Researching ASA404 in Cancer Treatment ATTRACT Clinical Trial Website Header – Blue Graphic ATTRACT Clinical Trial Website Header – Image of Couple
Home ATTRACT - 2

ATTRACT – 2

ATTRACT-2 (Antivascular Targeted Therapy: Researching ASA404 in Cancer Treatment-2) is a Phase III clinical trial which is being conducted at more than 180 sites in 20 countries. ATTRACT-2 is a randomized, double-blind, placebo-controlled, multi-center study of ASA404 in combination with docetaxel as second-line cancer treatment for advanced non-small cell lung cancer (NSCLC) of squamous or nonsquamous histology. The clinical trial will assign 900 NSCLC patients to one of the following cancer treatment arms in a 1:1 ratio: docetaxel plus ASA404 1800 mg/m2, or docetaxel plus placebo. Treatment is given for up to six 21-day cycles.